Logo Image
NEWS
All NewsFDA BriefsOncology IconsThe Targeted Pulse
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesPodcastsPractice PlaybookShortsVideo SeriesWebinars
PUBLICATIONS
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
  • NEWS
  • CONFERENCES
  • MEDIA
  • PUBLICATIONS
  • CASE-BASED ROUNDTABLE
  • PARTNERS
  • RESOURCES
  • SUBSCRIBE
  • BRAIN CANCER
  • BREAST CANCER
    • HER2 Breast Cancer
  • COMMUNITY ONCOLOGY PRACTICE
  • GENITOURINARY CANCERS
    • Bladder Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • GENOMIC TESTING
    • Liquid Biopsies
  • GI CANCERS
    • Pancreatic Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • GIST
    • HCC
  • GYNECOLOGIC CANCERS
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
  • HEAD & NECK CANCERS
  • HEMATOLOGY
    • Bone Marrow & Stem Cell Transplant
  • IMMUNOTHERAPY
    • CAR T-Cell Therapy
  • LEUKEMIAS
    • AML
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • LUNG CANCER
    • MET-Targeted Therapy
    • Small Cell Lung Cancer
    • Biomarker-Driven Lung Cancer
    • EGFR+ Lung Cancer
  • LYMPHOMAS
    • DLBCL
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • MPNs
  • MULTIPLE MYELOMA
  • NTRK GENE FUSIONS
  • ONCOLOGY POLICY
  • SARCOMA
  • SKIN CANCERS
    • Melanoma
  • THYROID CANCERS
Spotlight -
Community Oncology Practice|
Oncology Policy|
Myeloma|
CLL|
Genomic Testing|
GU Cancers
Advertisement

Theodore W. Laetsch, MD

Advertisement

Articles by Theodore W. Laetsch, MD

Larotrectinib Does Not Increase Risk of Fractures for Thyroid Cancer

ByTheodore W. Laetsch, MD
March 23rd 2022

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Advertisement

Latest Updated Articles

  • Larotrectinib Does Not Increase Risk of Fractures for Thyroid Cancer
    Larotrectinib Does Not Increase Risk of Fractures for Thyroid Cancer

    March 23rd 2022



Advertisement
Advertisement

Trending on Targeted Onc

1

Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML

2

FDA Removes PCNSL Limitation From Liso-Cel Label

3

FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC

4

FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC

5

FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastric Cancer

  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • Editorial Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us